Equities analysts expect that OpGen, Inc. (NASDAQ:OPGN) will post ($0.11) earnings per share for the current quarter, Zacks reports. Two analysts have made estimates for OpGen’s earnings, with the highest EPS estimate coming in at ($0.08) and the lowest estimate coming in at ($0.14). OpGen reported earnings per share of ($0.23) in the same quarter last year, which suggests a positive year-over-year growth rate of 52.2%. The business is expected to issue its next quarterly earnings report on Monday, October 23rd.

According to Zacks, analysts expect that OpGen will report full year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.67) to ($0.42). For the next year, analysts anticipate that the company will report earnings of ($0.31) per share, with EPS estimates ranging from ($0.45) to ($0.16). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for OpGen.

A number of brokerages have weighed in on OPGN. Zacks Investment Research cut OpGen from a “buy” rating to a “hold” rating in a research report on Wednesday, September 13th. HC Wainwright reiterated a “buy” rating and set a $1.00 price objective on shares of OpGen in a research note on Monday, September 11th. Finally, Dawson James reiterated a “buy” rating on shares of OpGen in a research note on Monday, June 19th.

In other news, Chairman Jven Capital, Llc purchased 1,875,000 shares of OpGen stock in a transaction on Tuesday, July 18th. The shares were purchased at an average cost of $0.40 per share, for a total transaction of $750,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Timothy C. Dec acquired 65,000 shares of the firm’s stock in a transaction on Tuesday, July 18th. The shares were purchased at an average cost of $0.40 per share, for a total transaction of $26,000.00. Following the completion of the purchase, the chief financial officer now directly owns 118,966 shares of the company’s stock, valued at approximately $47,586.40. The disclosure for this purchase can be found here. Company insiders own 31.83% of the company’s stock.

A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. lifted its stake in OpGen, Inc. (NASDAQ:OPGN) by 1.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the period. Vanguard Group Inc. owned 1.25% of OpGen worth $219,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/04/0-11-earnings-per-share-expected-for-opgen-inc-opgn-this-quarter-2.html.

OpGen (NASDAQ OPGN) opened at 0.306 on Wednesday. The firm’s market capitalization is $15.78 million. OpGen has a 1-year low of $0.25 and a 1-year high of $3.10. The firm’s 50-day moving average is $0.30 and its 200-day moving average is $0.30.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.